Venetoclax in the Context of the Current CLL Treatment Paradigm
In this podcast interview, Dr. William Wierda discusses the role of venetoclax in treating patients with chronic lymphocytic leukemia, particularly in light of recent trial results.
Immunotherapy and Hyperprogression of Disease
Drs. Kurzrock and Kato discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
The Re-emergence of Gemtuzumab Ozogamicin for AML
In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.
Role of PARP Inhibitors in Triple-Negative Breast Cancer
Dr. Judy Garber offers further perspective on the topic of PARP inhibitors in triple-negative breast cancer, which she presented in an education session at 2017 ESMO.
The Significance of Breast Cancer–Driving Mutations in Noncoding Genomic Regions
A recent analysis of 360 primary breast cancer genomes has identified some potentially important cancer-driving mutations found within noncoding genomic regions.
Novel Quadruplet Therapy Shows Promise in Multiple Myeloma
In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.
Next-Generation Sequencing for Sarcoma
We spoke with Mrinal M. Gounder, MD, about next-generation sequencing for sarcoma, and how it can be used to inform treatment decisions and prognosis.
Lung Cancer Immunotherapy Updates From ASCO
In this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.
Novel Nanomedicine Development for Glioblastoma
We spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.
Incorporating Immunotherapy-Related Biomarkers Into Clinical Practice
Dr. Karen Reckamp talks about ways to incorporate biomarkers for the treatment of lung cancer with immunotherapy into clinical practice at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago.